How AVEO Pharmaceuticals, Inc. (AVEO) Stacks Up Against Its Peers?

Judging by the fact that AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has encountered bearish sentiment from hedge fund managers, we can see that there exists a select few funds that slashed their entire stakes last quarter. It’s worth mentioning that Ori Hershkovitz’s Nexthera Capital said goodbye to the largest position of all the investors tracked by Insider Monkey, valued at close to $0.5 million in stock. Nathan Fischel’s fund, DAFNA Capital Management, also dropped its stock, about $0.2 million worth.

Let’s now take a look at hedge fund activity in other stocks similar to AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). These stocks are Rentech, Inc. (NYSEAMEX:RTK), Vericel Corp (NASDAQ:VCEL), Intec Pharma Ltd (NASDAQ:NTEC), and Vermillion, Inc. (NASDAQ:VRML). All of these stocks’ market caps resemble AVEO’s market cap.

As you can see these stocks had an average of 5 hedge funds with bullish positions and the average amount invested in these stocks was $9 million. That figure was $8 million in AVEO’s case. Rentech, Inc. (NYSEAMEX:RTK) is the most popular stock in this table. On the other hand Intec Pharma Ltd (NASDAQ:NTEC) is the least popular one with only 4 bullish hedge fund positions. Compared to these stocks AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) is more popular among hedge funds. Considering that hedge funds are fond of this stock in relation to its market cap peers, it may be a good idea to analyze it in detail and potentially include it in your portfolio.

Disclosure: None